文献速递浆细胞疾病MDS 与骨髓增殖性肿瘤血栓与止血

芳香化酶是 cereblon 的新型新底物,介导免疫调节药物诱导的血小板减少

Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia.
PubMed 文献 · Blood · 2020-01-01

该研究探索 IMiDs 诱导血小板减少的分子机制。在人类巨核细胞中,IMiDs 通过抑制自分泌雌二醇信号强烈损害前血小板形成,并鉴定芳香化酶为 cereblon 新型新底物,IMiDs 促进其泛素-蛋白酶体降解。接受 IMiD 治疗发生血小板减少的多发性骨髓瘤患者骨髓中芳香化酶显著降解,提示芳香化酶降解是 IMiD 诱导血小板减少的原因。

要点

  • IMiDs 通过抑制巨核细胞自分泌雌二醇信号损害前血小板形成。
  • 芳香化酶是 cereblon 新型新底物,IMiDs 促进其蛋白酶体依赖性降解。
  • IMiD 治疗伴血小板减少的骨髓瘤患者骨髓中芳香化酶显著降解。

核心结论

  • 芳香化酶是 cereblon 的新型新底物,负责 IMiD 诱导的血小板减少。

研究设计与样本

  • 基础与转化研究:在人类巨核细胞中探讨 IMiDs 对前血小板形成的影响,并鉴定 cereblon 新底物。
  • 纳入接受 IMiD 治疗并发生血小板减少的多发性骨髓瘤患者,检测骨髓芳香化酶降解。

主要发现

  • IMiDs 通过抑制人类巨核细胞自分泌雌二醇信号强烈损害前血小板形成。
  • IMiDs 促进芳香化酶招募至 cereblon,导致其蛋白酶体依赖性降解。
  • IMiD 治疗发生血小板减少的多发性骨髓瘤患者骨髓中芳香化酶显著降解。

临床怎么用

  • 监测 IMiD 治疗患者血小板减少时,可关注芳香化酶降解机制及雌二醇信号受损。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory drugs (IMiDs) are key agents for the treatment of multiple myeloma and myelodysplastic syndrome with chromosome 5q deletion. IMiDs exert their pleiotropic effects through the recruitment of neosubstrates to cereblon, a substrate receptor of the E3 ubiquitin ligase complex; therefore, identification of cell-specific neosubstrates is important to understand the effects of IMiDs. In clinical practice, IMiDs induce thrombocytopenia, which frequently results in the discontinuation of IMiD treatment. In the current study, we sought to identify the molecular mechanism underlying thrombocytopenia induced by IMiD treatment. We found that IMiDs strongly impaired proplatelet formation, a critical step in functional platelet production, through the inhibition of autocrine estradiol signaling in human megakaryocytes. Furthermore, we identified aromatase, an indispensable enzyme for estradiol biosynthesis, as a novel neosubstrate of cereblon. IMiDs promoted the recruitment of aromatase to cereblon, resulting in the degradation of aromatase in a proteasome-dependent manner. Finally, aromatase was significantly degraded in the bone marrow of patients with multiple myeloma who developed thrombocytopenia with IMiD treatment. These data suggest that aromatase is a neosubstrate of cereblon that is responsible for IMiD-induced thrombocytopenia.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tochigi T, Miyamoto T, Hatakeyama K, et al. Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia. Blood. 2020. PMID: 32219443. doi:10.1182/blood.2019003749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。